Technology & Business Strategy for Biologics and Advanced Therapies

The biologics and advanced-therapy landscape is rapidly evolving with innovations across monoclonal antibodies, biosimilars, cell therapies, gene therapies and emerging therapeutic platforms. Organisations need a strong understanding of technology trends, market dynamics and business strategy to make informed portfolio and investment decisions. This one-day program provides a strategic view of biologics and advanced therapies, combining scientific understanding with business and commercial considerations. Participants explore technology platforms, development pathways, market opportunities, competitive intelligence, manufacturing considerations and commercialisation strategies. The program helps cross-functional leaders understand how scientific innovation translates into business value and sustainable market advantage. Through industry cases and strategic exercises, participants develop frameworks for evaluating opportunities, risks and investment priorities across biologics and advanced-therapy portfolios.

Who Should Attend

• Pharma Strategy and Business Development teams
• R&D and CMC Leaders
• Biologics Portfolio Managers
• Innovation and Transformation teams
• Commercial and Market Access professionals
• Manufacturing and MSAT leaders
• Corporate Development teams
• Senior professionals involved in biologics investment decisions

Business Outcomes

• Understand the current biologics and advanced-therapy ecosystem.
• Evaluate technology platforms and their strategic relevance.
• Assess opportunities across emerging therapeutic modalities.
• Identify key business, regulatory and manufacturing considerations.
• Improve cross-functional alignment between scientific and commercial teams.
• Develop structured frameworks for technology evaluation and portfolio decisions.
• Understand factors influencing successful biologics commercialization.